Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Lushang Freda PharmaceuticalLtd Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Lushang Freda PharmaceuticalLtd has a total shareholder equity of CN¥4.7B and total debt of CN¥564.8M, which brings its debt-to-equity ratio to 11.9%. Its total assets and total liabilities are CN¥6.3B and CN¥1.6B respectively. Lushang Freda PharmaceuticalLtd's EBIT is CN¥175.5M making its interest coverage ratio -1.7. It has cash and short-term investments of CN¥3.2B.
Anahtar bilgiler
11.9%
Borç/özkaynak oranı
CN¥564.79m
Borç
| Faiz karşılama oranı | -1.7x |
| Nakit | CN¥3.24b |
| Eşitlik | CN¥4.73b |
| Toplam yükümlülükler | CN¥1.61b |
| Toplam varlıklar | CN¥6.35b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares
Jun 21
Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?
Apr 16Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations
Mar 28Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)
Feb 27Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 600223's short term assets (CN¥4.5B) exceed its short term liabilities (CN¥1.5B).
Uzun Vadeli Yükümlülükler: 600223's short term assets (CN¥4.5B) exceed its long term liabilities (CN¥137.3M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 600223 has more cash than its total debt.
Borcun Azaltılması: 600223's debt to equity ratio has reduced from 398.6% to 11.9% over the past 5 years.
Borç Kapsamı: 600223's debt is well covered by operating cash flow (65.5%).
Faiz Kapsamı: 600223 earns more interest than it pays, so coverage of interest payments is not a concern.